It seems particularly important in the case of CYP3A4, which is involved in metabolism of about 50% of all pharmaceuticals, many of them used to control neurologic and psychiatric WD signs and symptoms, which occur in 40% (neurologic) and (10–25% psychiatric) WD patients. Here, CYP3A4 is linked to Wilson disease.